Body Composition Analysis in Patients Undergoing Chemoembolization

I

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Status

Completed

Conditions

Hepatocellular Carcinoma

Study type

Observational

Funder types

Other

Identifiers

NCT01777698
QMECR1

Details and patient eligibility

About

Hepatocellular carcinoma represents 80-90% of primary hepatic malignant tumors. 80% of patients with hepatocellular carcinoma are associated with cirrhosis. Chemoembolization is a process in which a chemotherapeutic agent is deposited directly into the hepatic tumor where the principal artery is embolized. Bioelectrical impedance bases its evaluation in a model where the body is conformed by two different compartments: fat mass and fat free mass. Bioelectrical impedance is complemented by vectorial analysis, which is independent to the state of hydration and is helpful to monitor any changes in corporal composition. It can be used as a control for the interpretation of the bioelectrical impedance.

Enrollment

21 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with hepato-renal disease
  • Patients with hepatocellular carcinoma that are put down to radiofrequency ablation
  • Patients with depression or any psiquiatric disease.
  • Patients that don't agree to participate in the project.

Exclusion criteria

  • Patients with hepatocellular carcinoma that are put down to radiofrequency ablation
  • Patients with depression or any psiquiatric disease.
  • Patients that don't agree to participate in the project.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems